8-K: Brainstorm Cell Therapeutics Amends Bylaws, Sets Date for 2025 Annual Meeting
8-K Filing
Brainstorm Cell Therapeutics reduces the quorum requirement for stockholder meetings and announces the date and deadlines for its 2025 Annual Meeting.
Summary
- Brainstorm Cell Therapeutics Inc. has amended its bylaws to reduce the quorum requirement for stockholder meetings from a majority to one-third of outstanding shares.
- The Board of Directors approved this change on April 20, 2025.
- The company also announced that its 2025 Annual Meeting of Stockholders will be held virtually on June 25, 2025, at 10:00 a.m. Eastern time.
- The record date for determining stockholders eligible to vote at the meeting is May 7, 2025.
- Stockholders intending to submit proposals for inclusion in the proxy statement must do so by May 7, 2025.
- Stockholders who wish to make a proposal at the 2025 Annual Meeting (other than a proposal intended for inclusion in the Company's proxy statement for the 2025 Annual Meeting in accordance with Rule 14a-8) must notify the Company not later than May 7, 2025.
- Stockholders intending to solicit proxies in support of director nominees other than the Company's nominees pursuant to Rule 14a-19 must provide notice that sets forth the information required by Rule 14a-19 no later than May 1, 2025.
Sentiment
Score: 5
Explanation: The announcement is neutral, relating to standard corporate governance procedures.
Positives
- Reducing the quorum requirement may make it easier to conduct stockholder meetings.
Future Outlook
The company is preparing for its 2025 Annual Meeting of Stockholders.
Industry Context
This announcement is a routine corporate update regarding governance and shareholder meetings, typical for publicly traded companies.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Bylaws Amendment | Reduced quorum requirement for stockholder meetings from a majority to one-third of outstanding shares. | April 20, 2025 | May make it easier to conduct stockholder meetings. |
Stakeholder Impact
- Shareholders are impacted by the change in quorum requirements and the deadlines for submitting proposals and nominations.
Next Steps
- Stockholders need to adhere to the deadlines for submitting proposals and director nominations.
- The company will prepare and distribute proxy materials for the 2025 Annual Meeting.
Key Dates
| Date | Description |
|---|---|
| March 21, 2007 | Amendment No. 1 to the Bylaws of Brainstorm Cell Therapeutics Inc. |
| August 16, 2024 | Filing date of the Company's proxy statement for the 2024 Annual Meeting of Stockholders with the SEC. |
| September 16, 2024 | Date of the Company's 2024 Annual Meeting of Stockholders. |
| April 20, 2025 | Board of Directors approves amendment to bylaws and sets date for 2025 Annual Meeting. |
| May 1, 2025 | Deadline for stockholders intending to solicit proxies in support of director nominees other than the Company's nominees pursuant to Rule 14a-19. |
| May 7, 2025 | Record date for the 2025 Annual Meeting of Stockholders and deadline for stockholder proposals for inclusion in the proxy statement. |
| June 25, 2025 | Date of the 2025 Annual Meeting of Stockholders. |
Keywords
Annual Meeting, Stockholders, Bylaws, Quorum, Proxy, Director Nomination, Brainstorm Cell Therapeutics
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.